514 related articles for article (PubMed ID: 27653912)
1. Maintenance immunosuppression in myasthenia gravis.
Gotterer L; Li Y
J Neurol Sci; 2016 Oct; 369():294-302. PubMed ID: 27653912
[TBL] [Abstract][Full Text] [Related]
2. Maintenance immunosuppression in myasthenia gravis, an update.
Morren J; Li Y
J Neurol Sci; 2020 Mar; 410():116648. PubMed ID: 31901719
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic options in autoimmune myasthenia gravis.
García-Carrasco M; Escárcega RO; Fuentes-Alexandro S; Riebeling C; Cervera R
Autoimmun Rev; 2007 Jun; 6(6):373-8. PubMed ID: 17537383
[TBL] [Abstract][Full Text] [Related]
4. Myasthenia gravis: options and timing of immunomodulatory treatment.
Spring PJ; Spies JM
BioDrugs; 2001; 15(3):173-83. PubMed ID: 11437683
[TBL] [Abstract][Full Text] [Related]
5. [Therapeutic strategy in myasthenia gravis].
Tranchant C
Rev Neurol (Paris); 2009 Feb; 165(2):149-54. PubMed ID: 19233080
[TBL] [Abstract][Full Text] [Related]
6. Immunosuppressive therapies in myasthenia gravis.
Sanders DB; Evoli A
Autoimmunity; 2010 Aug; 43(5-6):428-35. PubMed ID: 20166870
[TBL] [Abstract][Full Text] [Related]
7. Current and future standards in treatment of myasthenia gravis.
Gold R; Schneider-Gold C
Neurotherapeutics; 2008 Oct; 5(4):535-41. PubMed ID: 19019304
[TBL] [Abstract][Full Text] [Related]
8. [Therapy of myasthenia gravis].
Rilling G; Tettenborn B
Praxis (Bern 1994); 2001 Aug; 90(33):1350-4. PubMed ID: 11534319
[TBL] [Abstract][Full Text] [Related]
9. Treatment-refractory myasthenia gravis.
Silvestri NJ; Wolfe GI
J Clin Neuromuscul Dis; 2014 Jun; 15(4):167-78. PubMed ID: 24872217
[TBL] [Abstract][Full Text] [Related]
10. Overview of myasthenia gravis.
Arora Y; Li Y
Hosp Pract (1995); 2013; 41(4):40-50. PubMed ID: 24145588
[TBL] [Abstract][Full Text] [Related]
11. Myasthenia gravis.
Silvestri NJ; Wolfe GI
Semin Neurol; 2012 Jul; 32(3):215-26. PubMed ID: 23117946
[TBL] [Abstract][Full Text] [Related]
12. Mycophenolate mofetil and myasthenia gravis.
Ciafaloni E
Lupus; 2005; 14 Suppl 1():s46-9. PubMed ID: 15803932
[TBL] [Abstract][Full Text] [Related]
13. Treatment of autoimmune myasthenia gravis.
Richman DP; Agius MA
Neurology; 2003 Dec; 61(12):1652-61. PubMed ID: 14694025
[TBL] [Abstract][Full Text] [Related]
14. Ocular myasthenia gravis: response to long-term immunosuppressive treatment.
Sommer N; Sigg B; Melms A; Weller M; Schepelmann K; Herzau V; Dichgans J
J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):156-62. PubMed ID: 9048716
[TBL] [Abstract][Full Text] [Related]
15. [Plasma exchange combined with immunosuppressive therapy in myasthenia gravis].
Tanaka M; Nagai H; Mori S; Miyatake T; Shinada S
No To Shinkei; 1982 Jul; 34(7):699-703. PubMed ID: 7138697
[No Abstract] [Full Text] [Related]
16. Current and emerging treatments for the management of myasthenia gravis.
Sathasivam S
Ther Clin Risk Manag; 2011; 7():313-23. PubMed ID: 21845054
[TBL] [Abstract][Full Text] [Related]
17. Myasthenia gravis: an update for the clinician.
Sieb JP
Clin Exp Immunol; 2014 Mar; 175(3):408-18. PubMed ID: 24117026
[TBL] [Abstract][Full Text] [Related]
18. Mycophenolate mofetil substitution for cyclosporine-dependent myasthenia gravis and nephrotoxicity.
Lim AK; Donnan G; Chambers B; Ierino FL
Intern Med J; 2007 Jan; 37(1):55-9. PubMed ID: 17199845
[TBL] [Abstract][Full Text] [Related]
19. Myasthenia gravis: emerging new therapy options.
Sieb JP
Curr Opin Pharmacol; 2005 Jun; 5(3):303-7. PubMed ID: 15907918
[TBL] [Abstract][Full Text] [Related]
20. Treatment and clinical research in myasthenia gravis: how far have we come?
Barohn RJ
Ann N Y Acad Sci; 2008; 1132():225-32. PubMed ID: 18567872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
